id: NEW:nonalcoholic_fatty_liver_disease_nafld_to_liver_disease_mortality
name: Nonalcoholic Fatty Liver Disease (NAFLD) â†’ Liver Disease Mortality
from_node:
  node_id: NEW:nonalcoholic_fatty_liver_disease_nafld
  node_name: Nonalcoholic Fatty Liver Disease (NAFLD)
to_node:
  node_id: liver_disease_mortality
  node_name: Liver Disease Mortality
direction: positive
category: biological
mechanism_pathway:
- 'Step 1: NAFLD initiates hepatic steatosis with fat accumulation in liver cells,
  triggering inflammatory responses and oxidative stress'
- 'Step 2: Chronic hepatic inflammation leads to progressive fibrosis, with documented
  incidence of 49.0 per 1,000 person-years for fibrosis progression'
- 'Step 3: Continued fibrosis advances to cirrhosis (incidence 10.9 per 1,000 person-years),
  with decompensated cirrhosis rates increasing over time'
- 'Step 4: Advanced liver disease may progress to hepatocellular carcinoma (incidence
  3.39 per 1,000 person-years) or require liver transplant (incidence 12.0 per 1,000
  person-years)'
- 'Step 5: Terminal liver complications result in liver-related mortality at an incidence
  of 3.10 per 1,000 person-years'
evidence:
  quality_rating: A
  n_studies: 79
  primary_citation: 'M. Le et al. 2024. Global incidence of adverse clinical events
    in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clinical
    and Molecular Hepatology.'
  supporting_citations: []
description: NAFLD progresses through a well-documented cascade of liver damage leading
  to mortality. This meta-analysis of 79 studies (1,377,466 persons) quantified incidence
  rates showing liver-related mortality at 3.10 per 1,000 person-years, with intermediate
  events including fibrosis progression (49.0), cirrhosis (10.9), HCC (3.39), and
  liver transplant (12.0) per 1,000 person-years. The overall incidence of liver-related
  events was 24.3 per 1,000 person-years.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: 3.1
    type: incidence_rate_per_1000_person_years
    ci_lower: null
    ci_upper: null
  p_value: null
  sample_size: 1377466
moderators:
- name: NASH status
  direction: strengthens
  strength: moderate
  description: Biopsy-proven NASH had significantly higher incidence of HCC compared
    to non-NASH (P=0.043), suggesting NASH accelerates progression to severe liver
    outcomes
- name: Geographic region
  direction: strengthens
  strength: moderate
  description: North America and Europe show higher mortality rates; Western Pacific/Southeast
    Asia shows higher HCC rates
- name: Time period
  direction: strengthens
  strength: weak
  description: Increasing rates of decompensated cirrhosis over time suggest worsening
    liver-related outcomes in recent periods
